scholarly journals Recanalization rate and clinical outcome of intravenous tissue plasminogen activator at 0.6mg/kg and intra-arterial urokinase in acute ischemic stroke with large vessel occlusion

Nosotchu ◽  
2008 ◽  
Vol 30 (6) ◽  
pp. 915-919 ◽  
Author(s):  
Kazuya Nakashima ◽  
Hideyuki Ohnishi ◽  
Katsushi Taomoto ◽  
Yoshihiro Kuga ◽  
Tsugumichi Ichioka ◽  
...  
Stroke ◽  
2020 ◽  
Vol 51 (Suppl_1) ◽  
Author(s):  
Yinn Cher Ooi ◽  
Faisal Mukarram ◽  
Honda Tristan ◽  
Naoki Kaneko ◽  
May Nour ◽  
...  

Introduction: Current guidelines recommend administration of intravenous tissue plasminogen activator (IVT) for all eligible patients with acute ischemic stroke (AIS) with large vessel occlusion (LVO). Recent observational data question the safety and efficacy of IVT in AIS patients with LVO undergoing mechanical thrombectomy (MT). Methods: Retrospective analysis using prospectively collected database on all AIS patients with LVO treated at our institution over 3 consecutive years. Stroke outcomes and adverse events were compared between patients who underwent IVT+MT versus MT only. Stroke outcomes were adjusted for known comorbidities, last know well time and core volume on pretreatment imaging. Results: 158 AIS patients with LVO were treated. 69 patients had treatment strategy of IVT+MT, 89 patients MT only. 7 (10%) patients treated with IVT had successful reperfusion before MT. IVT+MT, compared with MT alone, was associated with reduced 90day mortality (22.4% vs 40.8%, p:0.03) and reduced 90day severe disability or death (mRS 4-6: 48% vs 67%, p:0.03). Door-to-puncture time (DTP) was longer with IVT. IVT was not associated with increased intracranial hemorrhage but was associated with increased access site hematomas (16.9% vs 5.7%, p:0.03). Both groups showed similar proportion of patients ≥TICI2c (IVT+MT: 48% vs MT: 47%), however IVT+MT patients had greater proportion of TICI2c than TICI3. (IVT+MT TICI2c:30.4% vs MT TICI2c:17%) Conclusions: IVT before MT in AIS with LVO, results in reperfusion prior to thrombectomy in 10% of patients, and is associated with reduced mortality and severe disability at 90days. However, IVT+MT is associated with more access site hematomas and increased TICI 2C vs TICI 3 reperfusion, suggesting increased distal embolization due to thrombus fragmentation. The use of balloon guide for proximal flow arrest and aspiration during thrombectomy should be considered.


2020 ◽  
pp. 194187442097730
Author(s):  
Vincent A. LaBarbera ◽  
Aidan Azher ◽  
Mahesh V. Jayaraman ◽  
Linda C. Wendell ◽  
Daniel C. Sacchetti ◽  
...  

We report on the use of systemic heparinization following thrombolysis with intravenous tissue plasminogen activator (t-PA) for acute ischemic large vessel stroke, in the setting of COVID-19-induced hypercoagulability, with partial recanalization of the internal carotid artery. Off-label systemic heparinization was used within 12 hours of t-PA administration, after extensive multidisciplinary collaboration and family discussion, given evidence of severe hypercoagulability. We conclude that thrombolysis should be considered for all eligible patients with suspected or confirmed COVID-19 and acute ischemic stroke, and systemic anticoagulation, although with inherent risks, may be a useful adjunct treatment modality in selected patients who have received intravenous thrombolysis.


Stroke ◽  
1998 ◽  
Vol 29 (1) ◽  
pp. 18-22 ◽  
Author(s):  
David Chiu ◽  
Derk Krieger ◽  
Carlos Villar-Cordova ◽  
Scott E. Kasner ◽  
Lewis B. Morgenstern ◽  
...  

Stroke ◽  
2013 ◽  
Vol 44 (suppl_1) ◽  
Author(s):  
Gregg C Fonarow ◽  
Eric E Smith ◽  
Xin Zhao ◽  
Eric D Peterson ◽  
Ying Xian ◽  
...  

Background: The benefits of intravenous tissue-plasminogen activator (tPA) in acute ischemic stroke are time-dependent and several strategies have been reported to be associated with more rapid door-to-needle (DTN) times. However, the extent to which hospitals are utilizing these strategies has not been well studied. Methods: We surveyed 304 hospitals joining Target: Stroke regarding their baseline use of strategies to reduce door-to-needle times in the 1/2008-2/2010 timeframe (prior to the initiation of Target: Stroke). The survey was developed based on literature review and expert consensus for strategies identified as being associated with shorter DTN times and further refined after pilot testing. Categorical responses are reported as frequencies. Results: Hospitals participating in the survey were 50% academic, median 163 (IQR 106-247) ischemic stroke admissions per year, median 10 (IQR 6-17) tPA treated patients per year, and had median 79 minute (IQR 71-89) DTN times. By survey, 214 of 304 hospitals (70%) reported initiating or revising strategies to reduce DTN times in the prior 2 years. Reported use of the different strategies varied in frequency, with use of ischemic stroke critical pathways, CT scanner located in the Emergency Department, and tPA being stored in the Emergency Department being the strategies least frequently employed (Table). As part of Target: Stroke participation, 279 of 304 hospitals (91.5%) indicated they planned to have a dedicated team focused on reducing DTN times. Conclusions: While most US hospitals participating in this survey report use of the strategies to improve the timeliness of tPA administration for acute ischemic stroke, significant variation exists. Further research is needed to understand which of these strategies are most effective in improving acute ischemic stroke care.


Sign in / Sign up

Export Citation Format

Share Document